...mos and 104 completed 6 mos of treatment. 3 pts experienced one grade 3 toxicity. No cardiac toxicities were observed. B...
...MOS) sleep scale, MOS sexual function scale, and EuroQOL survey. Estrogens and inflammatory markers (interleukins 6 and ...
...Most pts had metastatic disease of gastric origin at initial diagnosis. KIT exon 11 mutations were most frequent. The me...
10519 Background: Primary resistance to imatinib in pts with advanced GIST is uncommon but after durable benefit, most p...
...mos and 12 mos, median PFS, quality of life and toxicity. The analysis of 1p/19q status by FISH and MGMT promoter methyl...
...mos. With a median follow-up of 5.1 mos, 2 pts were still receiving chemotherapy, 3 were lost to follow-up, and 18 compl...
...mos (95% CI 2.3, 5.0).,The combination of capecitabine, oxaliplating and cetuximab is tolerable for most patients, altho...
...mos. for Arm A and 10.8 mos. for Arm B; to date 52 pts in Arm A and 8 in Arm B have completed planned therapy. Median pr...
...mos.) and 6 from short-term (< 5 mos.) survivors. Multiple slide sections taken from each paraffin block were either mic...
...mos and there was no statistical difference between the survival curves of the two study arms (log-rank test: P>0.05).,T...
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话: 0531-88819269